More specifically, a recent study showed that the PMT enhancer of zeste homologue 2 (EZH2) and DNA-methyltransferase 1 (DNMT-1) transcriptionally repress Th1-type chemokines, CXCL9 and CXCL10, and that inhibition of both EZH2 and DNMT-1 increased CD8+ T-cell trafficking, reduced tumor growth and improved the efficacy of PD-L1 checkpoint blockade in a mouse ovarian cancer model [10]. This evidence concerns the gene CD8A and neoplasm.